| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Although favipiravir is approved as an anti-influenza virus drug, it also has antiviral effects of other RNA viruses. The aim of this study is to investigate the most effective compounds for several RNA viruses with favipiravir and its derivatives.
Poliovirus strain Sabin type 1 was used and infected to infection African green monkey kidney cells (Vero cells) in this experiment. The antiviral effect was examined by plaque reduction methods. The drug focused on the 6-position fluorine of favipiravir, and used derivatives substituted with hydrogen, chlorine and bromine.It has been reported that derivatives substituted with hydrogen at position 6 more than favipiravir have higher antiviral effects for influenza viruses, however favipiravir was most effective for poliovirus.
|
